 Activating mutations in the BRAF gene are present in about 50 of human melanomas. BRAF inhibitors BRAFi inhibit the serine-threonine protein kinase BRAF, which plays a dominant role in the MAPK pathway influencing cell growth. MEK inhibitors MEKi inhibit MEK1 and MEK2, two regulatory proteins downstream of BRAF. 